189.67
price up icon2.04%   3.7201
 
loading
Schlusskurs vom Vortag:
$185.95
Offen:
$189.305
24-Stunden-Volumen:
162.45K
Relative Volume:
0.13
Marktkapitalisierung:
$27.83B
Einnahmen:
$9.53B
Nettoeinkommen (Verlust:
$1.29B
KGV:
21.54
EPS:
8.8057
Netto-Cashflow:
$1.97B
1W Leistung:
+5.10%
1M Leistung:
+4.56%
6M Leistung:
+28.45%
1J Leistung:
+59.59%
1-Tages-Spanne:
Value
$188.67
$191.00
1-Wochen-Bereich:
Value
$174.85
$191.00
52-Wochen-Spanne:
Value
$115.25
$202.41

Biogen Inc Stock (BIIB) Company Profile

Name
Firmenname
Biogen Inc
Name
Telefon
(781) 464-2000
Name
Adresse
225 BINNEY STREET, CAMBRIDGE, MA
Name
Mitarbeiter
7,500
Name
Twitter
@biogen
Name
Nächster Verdiensttermin
2026-04-29
Name
Neueste SEC-Einreichungen
Name
BIIB's Discussions on Twitter

Compare BIIB vs LLY, JNJ, ABBV, AZN, NVS

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
BIIB icon
BIIB
Biogen Inc
189.62 27.29B 9.53B 1.29B 1.97B 8.8057
LLY icon
LLY
Lilly Eli Co
918.20 806.72B 65.18B 20.64B 5.96B 22.59
JNJ icon
JNJ
Johnson Johnson
226.93 544.73B 96.36B 21.04B 19.70B 8.6488
ABBV icon
ABBV
Abbvie Inc
204.63 362.81B 61.16B 4.19B 17.82B 2.3614
AZN icon
AZN
Astrazeneca Plc
195.93 303.62B 58.80B 10.24B 8.98B 3.2788
NVS icon
NVS
Novartis Ag Adr
147.83 282.35B 54.72B 14.02B 15.32B 7.1855

Biogen Inc Stock (BIIB) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2026-04-20 Hochstufung Wells Fargo Equal Weight → Overweight
2026-04-14 Hochstufung Piper Sandler Neutral → Overweight
2026-02-20 Eingeleitet Barclays Equal Weight
2026-02-09 Bestätigt H.C. Wainwright Buy
2026-01-07 Fortgesetzt UBS Neutral
2025-12-10 Herabstufung HSBC Securities Hold → Reduce
2025-11-06 Hochstufung Stifel Hold → Buy
2025-09-25 Eingeleitet Jefferies Buy
2025-07-21 Fortgesetzt Truist Hold
2025-04-28 Herabstufung HSBC Securities Buy → Hold
2025-04-04 Herabstufung Argus Buy → Hold
2025-02-11 Eingeleitet Bernstein Mkt Perform
2025-01-02 Herabstufung Piper Sandler Overweight → Neutral
2024-12-20 Herabstufung BMO Capital Markets Outperform → Market Perform
2024-12-16 Herabstufung Stifel Buy → Hold
2024-12-10 Fortgesetzt BofA Securities Neutral
2024-12-09 Herabstufung Jefferies Buy → Hold
2024-11-18 Herabstufung Needham Buy → Hold
2024-11-15 Eingeleitet Wolfe Research Peer Perform
2024-11-14 Eingeleitet Citigroup Neutral
2024-10-31 Herabstufung Morgan Stanley Overweight → Equal-Weight
2024-10-10 Fortgesetzt Raymond James Mkt Perform
2024-02-14 Bestätigt Needham Buy
2024-02-14 Herabstufung Wells Fargo Overweight → Equal Weight
2024-01-24 Herabstufung UBS Buy → Neutral
2023-12-20 Fortgesetzt Cantor Fitzgerald Overweight
2023-12-07 Hochstufung Raymond James Mkt Perform → Outperform
2023-09-06 Eingeleitet HSBC Securities Buy
2023-07-27 Eingeleitet Scotiabank Sector Outperform
2023-07-24 Bestätigt UBS Buy
2023-05-01 Hochstufung Guggenheim Neutral → Buy
2023-04-17 Hochstufung Piper Sandler Neutral → Overweight
2022-10-26 Hochstufung Goldman Neutral → Buy
2022-10-13 Hochstufung Stifel Hold → Buy
2022-10-07 Hochstufung Argus Hold → Buy
2022-09-28 Hochstufung BMO Capital Markets Market Perform → Outperform
2022-09-28 Hochstufung Mizuho Neutral → Buy
2022-09-28 Hochstufung Robert W. Baird Neutral → Outperform
2022-04-18 Hochstufung Wells Fargo Equal Weight → Overweight
2022-03-08 Herabstufung Stifel Buy → Hold
2022-03-03 Hochstufung RBC Capital Mkts Sector Perform → Outperform
2022-02-04 Herabstufung BMO Capital Markets Outperform → Market Perform
2022-02-04 Bestätigt Barclays Equal Weight
2022-02-04 Bestätigt BofA Securities Neutral
2022-02-04 Bestätigt Cowen Outperform
2022-02-04 Bestätigt Morgan Stanley Overweight
2022-02-04 Bestätigt Needham Buy
2022-02-04 Bestätigt Oppenheimer Outperform
2022-02-04 Bestätigt RBC Capital Mkts Sector Perform
2022-02-04 Bestätigt Robert W. Baird Neutral
2022-02-04 Bestätigt Wedbush Neutral
2022-02-04 Bestätigt Wells Fargo Equal Weight
2022-02-04 Bestätigt Wolfe Research Peer Perform
2022-01-13 Herabstufung Guggenheim Buy → Neutral
2022-01-12 Herabstufung Piper Sandler Overweight → Neutral
2021-12-10 Fortgesetzt Raymond James Mkt Perform
2021-12-09 Fortgesetzt Wells Fargo Equal Weight
2021-12-06 Eingeleitet Goldman Neutral
2021-11-19 Eingeleitet BMO Capital Markets Outperform
2021-09-23 Eingeleitet Needham Buy
2021-06-18 Hochstufung Piper Sandler Neutral → Overweight
2021-06-14 Bestätigt Truist Buy
2021-06-11 Hochstufung Bernstein Mkt Perform → Outperform
2021-06-10 Hochstufung UBS Neutral → Buy
2021-06-08 Hochstufung Atlantic Equities Underweight → Neutral
2021-06-08 Bestätigt Barclays Equal Weight
2021-06-08 Hochstufung Citigroup Sell → Neutral
2021-06-08 Bestätigt H.C. Wainwright Buy
2021-06-08 Bestätigt Jefferies Buy
2021-06-08 Bestätigt Morgan Stanley Overweight
2021-06-08 Bestätigt RBC Capital Mkts Sector Perform
2021-06-08 Hochstufung Robert W. Baird Underperform → Neutral
2021-06-08 Bestätigt Stifel Buy
2021-06-08 Hochstufung William Blair Mkt Perform → Outperform
2021-06-07 Hochstufung BofA Securities Underperform → Neutral
2021-06-07 Hochstufung Cowen Market Perform → Outperform
2021-06-07 Hochstufung Raymond James Underperform → Mkt Perform
2021-02-05 Herabstufung DZ Bank Buy → Hold
2021-01-29 Hochstufung Stifel Hold → Buy
2020-11-10 Hochstufung DZ Bank Hold → Buy
2020-11-09 Herabstufung Atlantic Equities Neutral → Underweight
2020-11-09 Herabstufung BofA Securities Neutral → Underperform
2020-11-09 Herabstufung Cowen Outperform → Market Perform
2020-11-09 Bestätigt H.C. Wainwright Buy
2020-11-04 Hochstufung BofA Securities Underperform → Neutral
2020-11-04 Hochstufung Jefferies Hold → Buy
2020-11-04 Hochstufung Wells Fargo Equal Weight → Overweight
2020-10-28 Eingeleitet UBS Neutral
2020-07-27 Hochstufung Morgan Stanley Underweight → Overweight
2020-06-22 Herabstufung Barclays Overweight → Equal Weight
2020-06-22 Bestätigt RBC Capital Mkts Sector Perform
2020-06-09 Herabstufung Bernstein Outperform → Mkt Perform
2020-04-23 Herabstufung Citigroup Neutral → Sell
2020-04-23 Herabstufung Raymond James Mkt Perform → Underperform
2020-03-31 Eingeleitet Wolfe Research Peer Perform
2020-02-27 Eingeleitet Barclays Overweight
2020-01-27 Hochstufung Canaccord Genuity Hold → Buy
2019-12-13 Hochstufung Credit Suisse Underperform → Neutral
2019-12-02 Herabstufung Robert W. Baird Neutral → Underperform
Alle ansehen

Biogen Inc Aktie (BIIB) Neueste Nachrichten

pulisher
06:09 AM

UBS Upgrades Biogen to Buy From Neutral, Adjusts Price Target to $225 From $185 - marketscreener.com

06:09 AM
pulisher
05:34 AM

Analyst recommendations: Albemarle, Biogen, Qualcomm, Twilio, Lyondellbasell… - marketscreener.com

05:34 AM
pulisher
04:14 AM

TJ Biopharma enters into agreement with Biogen for Felzartamab assets in Greater China Region - BioSpectrum Asia

04:14 AM
pulisher
03:51 AM

UBS upgrades Biogen stock rating on pipeline catalysts, raises target to $225 - Investing.com Canada

03:51 AM
pulisher
Apr 21, 2026

Stocks making big moves yesterday: Cadence Design Systems, JFrog, Lucid, Ulta, and Biogen - Yahoo Finance

Apr 21, 2026
pulisher
Apr 21, 2026

Biogen Inc. Secures Global Rights To Felzartamab Through Greater China Deal With TJ Biopharma - BioPharma APAC

Apr 21, 2026
pulisher
Apr 21, 2026

Biogen amasses full felzartamab rights with $850M TJ deal - BioWorld News

Apr 21, 2026
pulisher
Apr 21, 2026

BIIB Inks Deal to Acquire Rights to Felzartamab in China, Stock Up - TradingView

Apr 21, 2026
pulisher
Apr 21, 2026

3 Reasons to Avoid BIIB and 1 Stock to Buy Instead - Yahoo Finance

Apr 21, 2026
pulisher
Apr 21, 2026

Amyloid Setback: Future Possibilities For The Treatment Of Alzheimer's Disease - Seeking Alpha

Apr 21, 2026
pulisher
Apr 21, 2026

Biogen gets worldwide development and commercialization rights to felzartamab - The Pharma Letter

Apr 21, 2026
pulisher
Apr 20, 2026

Lobbying Update: $1,460,000 of BIOGEN lobbying was just disclosed - Quiver Quantitative

Apr 20, 2026
pulisher
Apr 20, 2026

Biogen (BIIB) Stock Trades Up, Here Is Why - Yahoo Finance

Apr 20, 2026
pulisher
Apr 20, 2026

Biogen Inc (BIIB) Shares Surge 3.4% -- What GF Score of 72 Tells Investors - GuruFocus

Apr 20, 2026
pulisher
Apr 20, 2026

Biogen Inc. stock (US09062X1037): Is its neurology focus strong enough to drive new upside? - AD HOC NEWS

Apr 20, 2026
pulisher
Apr 20, 2026

Biogen earnings preview: What to expect - MSN

Apr 20, 2026
pulisher
Apr 20, 2026

Biogen (BIIB) Secures Exclusive Rights to Felzartamab in Greater China - GuruFocus

Apr 20, 2026
pulisher
Apr 20, 2026

BIIB Upgraded by Wells Fargo -- Price Target Raised to $250 - GuruFocus

Apr 20, 2026
pulisher
Apr 20, 2026

Biogen Earnings Preview: What to Expect - Barchart.com

Apr 20, 2026
pulisher
Apr 20, 2026

Biogen to buy China rights to immune disease drug for up to $850M - Seeking Alpha

Apr 20, 2026
pulisher
Apr 20, 2026

Wells Fargo Upgrades Biogen to Overweight: Does the Alzheimer's Story Finally Have a Second Act? - 24/7 Wall St.

Apr 20, 2026
pulisher
Apr 20, 2026

Biogen buys China rights to immune disease drug in up to $850 million deal with TJ Biopharma - Reuters

Apr 20, 2026
pulisher
Apr 20, 2026

TJ Biopharma Enters into Agreement with Biogen for Felzartamab Assets in the Greater China Region - Tirto.id

Apr 20, 2026
pulisher
Apr 20, 2026

Biogen enters into agreement with TJ Biopharma for Felzartamab assets in the Greater China region - marketscreener.com

Apr 20, 2026
pulisher
Apr 20, 2026

Biogen acquires China rights to felzartamab for up to $850M By Investing.com - Investing.com Canada

Apr 20, 2026
pulisher
Apr 20, 2026

Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region - Biogen

Apr 20, 2026
pulisher
Apr 20, 2026

Biogen Enters Into Agreement With TJ Biopharma For Felzartamab Assets In The Greater China Region - marketscreener.com

Apr 20, 2026
pulisher
Apr 20, 2026

Wells Fargo Upgrades Biogen to Overweight From Equalweight, Adjusts PT to $250 From $200 - marketscreener.com

Apr 20, 2026
pulisher
Apr 19, 2026

Biogen Expands Targeted Therapy Pipeline With Apellis Deal And Alloy Alliance - Yahoo Finance

Apr 19, 2026
pulisher
Apr 18, 2026

Biogen Inc. (NASDAQ:BIIB) Rating Balance Draws Nasdaq Composite Attention - Kalkine Media

Apr 18, 2026
pulisher
Apr 18, 2026

Notable analyst calls this week: Tesla, Qualcomm and Biogen among top picks - Seeking Alpha

Apr 18, 2026
pulisher
Apr 18, 2026

Understanding Momentum Shifts in (BIIB) - Stock Traders Daily

Apr 18, 2026
pulisher
Apr 18, 2026

Biogen Inc. (NASDAQ:BIIB) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat

Apr 18, 2026
pulisher
Apr 17, 2026

Biogen secures FDA nod for higher dose of SMA drug Spinraza - MSN

Apr 17, 2026
pulisher
Apr 17, 2026

Should Value Investors Buy Biogen (BIIB) Stock? - Yahoo Finance

Apr 17, 2026
pulisher
Apr 17, 2026

Biogen CEO: China will match U.S. drug innovation in five to 10 years - The Business Journals

Apr 17, 2026
pulisher
Apr 17, 2026

Zacks.com featured highlights include Biogen, TE Connectivity and ZTO Express (Cayman) - The Globe and Mail

Apr 17, 2026
pulisher
Apr 16, 2026

Biogen Inc. stock underperforms Thursday when compared to competitors - MarketWatch

Apr 16, 2026
pulisher
Apr 16, 2026

Bulls and Biogen Team Up to Celebrate "America 250" with Triangle Community - MLB.com

Apr 16, 2026
pulisher
Apr 16, 2026

Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’ - BioWorld News

Apr 16, 2026
pulisher
Apr 16, 2026

'There's a lot of momentum': Biogen acquisition translates into West Coast hub with immunology focus - The Business Journals

Apr 16, 2026
pulisher
Apr 16, 2026

US FDA's accelerated approval for drugs needs more transparency, says research firm - marketscreener.com

Apr 16, 2026
pulisher
Apr 16, 2026

How Biogen’s Alloy ASO Deal Could Shape Its Neurology Pipeline Will Impact Biogen (BIIB) Investors - simplywall.st

Apr 16, 2026
pulisher
Apr 16, 2026

This Healthcare Stock Has Made Long-Term Investors Rich -- Can It Keep Doing It? - The Motley Fool

Apr 16, 2026
pulisher
Apr 15, 2026

Sumitomo Mitsui Trust Group Inc. Lowers Holdings in Biogen Inc. $BIIB - MarketBeat

Apr 15, 2026
pulisher
Apr 15, 2026

Biogen (BIIB) Valuation Check After Mixed Recent Returns And Growing Focus On LEQEMBI Growth Potential - Yahoo Finance

Apr 15, 2026
pulisher
Apr 14, 2026

Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch

Apr 14, 2026
pulisher
Apr 14, 2026

Piper Sandler upgrades Biogen stock rating on acquisition strength By Investing.com - Investing.com South Africa

Apr 14, 2026
pulisher
Apr 14, 2026

Piper Sandler upgrades Biogen stock rating on acquisition strength - Investing.com

Apr 14, 2026
pulisher
Apr 14, 2026

Biogen stock upgraded at Piper Sandler (BIIB:NASDAQ) - Seeking Alpha

Apr 14, 2026
pulisher
Apr 14, 2026

Biogen Secures FDA Nod for Higher Dose of SMA Drug Spinraza - Eastern Progress

Apr 14, 2026

Finanzdaten der Biogen Inc-Aktie (BIIB)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
PFE PFE
$27.06
price down icon 0.92%
$133.81
price down icon 1.71%
NVO NVO
$39.11
price down icon 1.14%
$346.45
price up icon 0.07%
MRK MRK
$112.12
price down icon 0.44%
NVS NVS
$148.22
price up icon 0.18%
Kapitalisierung:     |  Volumen (24h):